Friday, February 3, 2023
HomeHealth & FitnessDr. Galsky explains results of pivotal adjuvant immunotherapy trials in urothelial cancer

Dr. Galsky explains results of pivotal adjuvant immunotherapy trials in urothelial cancer

Matthew Galsky, MD, discusses the discordant results of the pivotal phase 3 CheckMate-274 and IMvigor010 trials of adjuvant immunotherapy in urothelial cancer.

In an interview during the SUO 23rd Annual Meeting, Matthew Galsky, MD, discussed the pivotal phase 3 CheckMate-274 IMvigor010 trials, and the how the results of the studies yielded discordant outcomes regarding the efficacy of adjuvant immunotherapy in urothelial cancer.

Galsky is a professor of Medicine and director of Genitourinary Medical Oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute.

Abdullah Anaman
Abdullah Anamanhttps://aanaman.me
I am a highly competent IT professional with a proven track record in designing websites, building apps etc. I have strong technical skills as well as excellent interpersonal skills, enabling me to interact with a wide range of clients.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!

Most Popular

Recent Comments